

## Supplemental Methods

### Details of the participants

HC individuals had no history of psychiatric illness or substance abuse. The exclusion criteria for all participants were a history of head trauma, neurological illness, and serious medical or surgical illness. Details of each site are as follows:

#### 1) Institute of Psychiatry, Psychology and Neuroscience (IoPPN)

Subjects at ultra-high risk (UHR) for psychosis and healthy controls (HC) were recruited between December 2009 and September 2011. UHR subjects were referred to IoPPN from the Outreach and Support in South London (OASIS) program. UHR was defined by the presentation of one or more of the following: 1) attenuated psychotic symptoms, 2) brief limited intermittent psychotic episode, and/or 3) genetic risk and deterioration syndrome. The comorbidities in UHR individuals included past or current depression ( $n = 13$ ), personality disorders ( $n = 5$ ), anxiety disorders ( $n = 5$ ), substance use ( $n = 4$ ), and body dysmorphic disorder ( $n = 1$ ). The Comprehensive Assessment of At-Risk Mental States (CAARMS) (1) was used for the diagnostic purpose at the intake assessment and when performing scans for the assessment of symptom severity. The latter are shown in [Table 1](#) in the main text. Details of the demographic and clinical data are also shown in [Table 1](#) in the main text. The HC subjects had no first-degree relatives with psychotic disorders.

#### 2) Johns Hopkins University (JHU)

Patients with first-episode psychosis (FEP) and HC were recruited between January 2014 and November 2015. Diagnosis was made based on the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). FEP included schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis NOS, and depression or bipolar disorder with hallucinations or delusions. The comorbidities of the FEP individuals included childhood or current diagnosis of autism ( $n = 2$ ) and attention-deficit/hyperactivity disorder ( $n = 2$ ), past history of anorexia nervosa ( $n = 1$ ), and trichotillomania ( $n = 1$ ). Forty-one patients were administered antipsychotics, four were unmedicated, and six were medicated but without information on the current dose. The HC subjects had no first-degree relatives with psychotic disorders. The demographic and clinical data are shown in [Supplemental Table 1](#).

#### 3) Kanazawa Medical University (KMU)

FEP and chronic psychosis (ChrP) patients, as well as HC, were recruited between November 2011 and August 2018. All patients were diagnosed as schizophrenia using SCID without comorbidity with other Axis I disorders. No patients were administered antipsychotics. HC

subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 2](#).

#### 4) Kyoto University (Kyoto)

ChrP and HC participants were recruited between October 2010 and June 2013. The diagnoses were made based on the SCID. ChrP included schizophrenia, schizoaffective disorder, and schizophreniform disorder. Patients were not comorbid with any other Axis I disorders. All patients were administered antipsychotics. HC subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 3](#).

#### 5) Osaka University (OSK2 and OSK3)

Patients with FEP and ChrP, as well as HC, were recruited between August 2011 and August 2013 (OSK2), and between February 2014 and January 2017 (OSK3). The diagnoses were confirmed using the SCID. All patients were diagnosed with schizophrenia, schizophreniform disorder, or brief psychotic disorder without comorbidity with other Axis I disorders. No patients were administered antipsychotics. HC subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 4 and 5](#).

#### 6) The University of Tokyo (Tokyo)

Patients with FEP and ChrP, as well as HC, were recruited between June 2014 and February 2019. All patients were diagnosed with schizophrenia without comorbidity with other Axis I disorders using SCID. All patients were administered antipsychotics. The details are shown in [Supplemental Table 6](#).

#### 7) University of Toyama (TYM)

Patients with FEP and ChrP, as well as HC, were recruited between April 2015 and May 2017. All patients were diagnosed with schizophrenia without comorbidity with other Axis I disorders based on the SCID. No patients were administered antipsychotics. The HC subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 7](#).

### **Magnetic Resonance Imaging (MRI) acquisition**

The parameters used at each site are shown in [Supplemental Table 8](#). All MRI images were visually checked, and subjects with gross artifacts or anatomical anomalies were excluded. Subjects with excessive head motion (mean framewise displacement (2) of  $> 0.5\text{mm}$ ) were also excluded.

## **ICA-denoising**

Independent component analysis (ICA)-based denoising was performed for each subject to clean up the resting-state functional MRI (rsfMRI) data, as described by Aso et al., 2017 (3). Normalized rsfMRI data were entered into MELODIC/FSL (<http://www.fmrib.ox.ac.uk/fsl>) without spatial smoothing to capture as many signal component of non-neuronal origin as possible. Instead of using a machine-learning based classifier (4, 5), we classified each subject's components as noise based on three objective criteria: 1) high-frequency power ratio ( $>0.1$  to  $0.2$  Hz or the Nyquist frequency for the repetition time [TR]) relative to  $<0.1$ Hz, 2) non-gray matter involvement index, and 3) slice dependency index calculated as the ratio of within- and between-slice spatial high-frequency components. Then the rsfMRI data were re-sampled into 3 mm and smoothed with 5-mm full-width at half-maximum.

## **Supplemental Results**

### **Effects of medication and psychosis type**

#### **1) Group comparison of within-network connectivity**

The mean values of significant cluster of the right thalamus in the midbrain-thalamic and striatal parts of the basal ganglia network (BGN-MbThal) did not differ between unmedicated and medicated FEP patients ( $p = 0.67$ , corrected for contrast) or between affective and non-affective FEP patients ( $p = 0.36$ , corrected for contrast).

The mean cluster value of anterior cingulate cortex (ACC)-insular system of the salience network (SN-ACC) remained significantly reduced in UHR ( $p < 0.001$ , corrected for contrast), after excluding a medicated patient (50mg quetiapine).

#### **2) Group comparison of the energy landscape analysis (ELA)**

The transition rate between two brain states did not differ between medication or psychosis types ( $p = 0.12$  and  $0.13$  respectively, corrected for contrast).

## Supplemental references

1. Yung AR, Yuen HP, McGorry PD, et al.: Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry* 2005; 39:964–971
2. Jenkinson M, Bannister P, Brady M, et al.: Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images. *NeuroImage* 2002; 17:825–841
3. Aso T, Jiang G, Urayama S, et al.: A Resilient, Non-neuronal Source of the Spatiotemporal Lag Structure Detected by BOLD Signal-Based Blood Flow Tracking [Internet]. *Front Neurosci* 2017; 11[cited 2018 Mar 28] Available from: <https://www.frontiersin.org/articles/10.3389/fnins.2017.00256/full>
4. Salimi-Khorshidi G, Douaud G, Beckmann CF, et al.: Automatic denoising of functional MRI data: Combining independent component analysis and hierarchical fusion of classifiers. *NeuroImage* 2014; 90:449–468
5. Griffanti L, Salimi-Khorshidi G, Beckmann CF, et al.: ICA-based artefact removal and accelerated fMRI acquisition for improved resting state network imaging. *NeuroImage* 2014; 95:232–247

**Supplemental Table 1. Demographic and clinical data of individuals recruited at Johns Hopkins University (JHU)**

	HC (73)	FEP (51)	Statistics	DoF	P
Age, mean years (SD)	24.1 (3.7)	22.6 (4.7)	t = 1.85	90.5	0.07
Age range, years	18-34	15-34			
Sex (female/male)	36/37	17/34	Chi-square = 3.1	1	0.1*
Ethnicity			Chi-square = 2.7	5	0.75
African	43	26			
Caucasian	26	19			
Asian	2	3			
Hispanic	0	1			
Mixed	1	1			
Unknown	1	1			
Education (year)	14.7 (2.1)	13.2 (3.1)	t = 3.0	82.1	0.004
Smoking (yes/no)	4/69	16/35	Chi-square = 14.9	1	< 0.001*
Cannabis use (yes/no)	2/71	11/37	Chi-square = 12.3	1	0.001*
Duration of illness (years)		1.3 (0.9)			
SAPS total		15.6 (20.0)			
SANS total		30.7 (21.9)			
PANSS positive **		13.0 (4.2)			
CP eq.		470.1 (321.6)			
tSNR	5065.2 (1563.0)	5065.0 (1963.3)	t = 0.001	122	1.00

\* Fisher's exact test.

\*\* Converted from SAPS.

### Abbreviations

CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; tSNR, temporal signal/noise ratio.

**Supplemental Table 2. Demographic and clinical data of individuals recruited at Kanazawa Medical University (KMU)**

	HC (15)	FEP (4) & ChrP (4)	Statistics	DoF	P
Age, mean years (SD)	29.7 (8.8)	32.0 (12.2)	$t = -0.53$	21	0.6
Age range, years	19-49	20-51			
Sex (female/male)	10/5	2/6	Chi-square = 3.6	1	0.09*
Ethnicity	All Japanese	All Japanese			
Education (year)	16.5 (1.6)	13.1 (1.8)	$t = 4.6$	20	< 0.001
Smoking	Not available	Not available			
Substance use	All negative	All negative			
Duration of illness (years)		3.1 (3.7)			
PANSS positive		17.4 (4.9)			
PANSS negative		18.8 (5.7)			
PANSS general		30.1 (6.7)			
CP eq		0			
tSNR	1866.9 (373.6)	2004.3 (493.5)	$t = -0.75$	21	0.46

\* Fisher's exact test.

#### **Abbreviations**

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 3. Demographic and clinical data of individuals recruited at Kyoto University (Kyoto)**

	HC (41)	ChrP (46)	Statistics	DoF	P
Age, mean years (SD)	36.3 (6.7)	39.0 (9.2)	t = -1.57	82.1	0.12
Age range, years	30-57	24-57			
Sex (female/male)	11/30	21/25	Chi-square = 3.3	1	0.08*
Ethnicity	All Japanese	All Japanese			
Education (years)	16.7 (2.2)	14.1 (2.2)	t = 5.26	81	< 0.001
Smoking (yes/no)	5/31	9/34	Chi-square = 0.67	1	0.56*
Substance use	All negative	All negative			
Duration of illness (years)		14.3 (7.8)			
PANSS positive		14.6 (5.1)			
PANSS negative		15.7 (5.6)			
PANSS general		29.6 (9.8)			
CP eq		591.8 (480.1)			
tSNR	1423.0 (334.5)	1681.7 (551.9)	t = -2.68	75.3	0.009

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 4. Demographic and clinical data of individuals recruited at OSAKA University MRI2 (OSK2).**

	HC (17)	FEP (2) & ChrP (7)	Statistics	DoF	P
Age, mean years (SD)	32.4 (15.4)	33.6 (16.2)	$t = -.186$	24	0.85
Age range, years	20-64	20-64			
Sex (female/male)	12/5	6/3	Chi-square = 0.042	1	1.00*
Ethnicity	All Japanese	All Japanese			
Education (years)	14.7 (2.4)	13.2 (1.9)	$t = 1.54$	24	0.14
Smoking (yes/no)	(0/17)	(2/7)			
Substance use	All negative	All negative			
Duration of illness (years)		8.2 (7.3)			
PANSS positive		18.7 (4.9)			
PANSS negative		20.3 (5.9)			
PANSS general		45.4 (9.8)			
CP eq		0			
tSNR	7950.8 (1176.9)	8559.7 (872.1)	$t = -1.36$	24	0.19

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 5. Demographic and clinical data of individuals recruited at OSAKA University MRI3 (OSK3).**

	HC (35)	FEP (7) & ChrP (14)	Statistics	DoF	P
Age, mean years (SD)	30.5 (11.3)	27.7 (8.0)	t = 1.01	54	0.32
Age range, years	18-66	16-43			
Sex (female/male)	19/16	11/10	Chi-square = 0.19	1	1.00*
Ethnicity	All Japanese	All Japanese			
Education (years)	14.9 (2.4)	13.4 (2.7)	t = 2.15	54	0.04
Smoking (yes/no)	5/30	0/21			
Substance use	All negative	All negative			
Duration of illness (years)		5.8 (5.6)			
PANSS positive		20.1 (4.2)			
PANSS negative		21.9 (4.3)			
PANSS general		47.2 (10.8)			
CP eq		0			
tSNR	17285.8 (2516.7)	20959.8 (4610.9)	t = -3.36	27.3	0.002

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 6. Demographic and clinical data of individuals recruited at the University of Tokyo (Tokyo).**

	HC (63)	FEP (14) & ChrP (26)	Statistics	DoF	P
Age, mean years (SD)	38.7 (8.2)	28.9 (10.0)	t = 5.43	101	< 0.001
Age range, years	25-59	16-52			
Sex (female/male)	37/26	17/23	Chi-square = 2.58	1	0.16*
Ethnicity	All Japanese	All Japanese			
Education (years)	15.8 (2.3)	13.4 (2.4)	t = 5.14	101	< 0.001
Smoking (yes/no)	6/57	4/31	Chi-square = 0.09	1	0.74*
Substance use	All negative	All negative			
Duration of illness (years)		8.6 (8.6)			
PANSS positive		16.2 (4.9)			
PANSS negative		19.0 (6.7)			
PANSS general		33.6 (7.7)			
CP eq		546.5 (431.3)			
tSNR	19682.8 (4260.1)	18862.8 (3209.5)	t = 1.04	101	0.3

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 7. Demographic and clinical data of individuals recruited at the University of Toyama (TYM).**

	HC (10)	FEP (3) & ChrP (2)	Statistics	DoF	P
Age, mean years (SD)	25.30 (5.67)	28.20 (7.91)	t = -.82	13	0.43
Age range, years	21-37	21-39			
Sex (female/male)	6/4	2/3	Chi-square = 0.54	1	0.61*
Ethnicity	All Japanese	All Japanese			
Education (years)	16.5 (1.6)	14.4 (1.7)	t = 2.38	13	0.03
Smoking	Not available	Not available			
Substance use	All negative	All negative			
Duration of illness (years)		3.2 (3.8)			
PANSS positive		15.8 (3.6)			
PANSS negative		17.0 (7.6)			
PANSS general		35.8 (8.4)			
CP eq		0			
tSNR	2610.6 (340.8)	2885.9 (512.3)	t = -1.25	13	0.23

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.


**Supplemental Table 8. Scanning parameters at each site.**

	IoPPN	JHU	KMU	Kyoto	OSK2	OSK3	Tokyo	TYM
Vendor	Siemens	Philips	Siemens	Siemens	GE	GE	GE	Siemens
Type	TimTRIO	Achieva	TimTRIO	TRIO	Signa HDxt	DISCOVERY MR750	DISCOVERY MR750w	Verio
Head coil (channel)	32	32	32	8	8	8	24	12
Magnetic field	3T (Tesla)	3T	3T	3T	3T	3T	3T	3T
T1-weighted image								
Sequence	MP2RAGE	MPRAGE	MPRAGE	MPRAGE	FSPGR	FSPGR	FSPGR	MPRAGE
Repetition time (ms)	5000	6.8	1420	2000	7.2	8.16	7.65	2300
Echo time (ms)	2.96	3.1	2.08	4.38	2.9	3.17	3.1	2.9
Inversion time (ms)	700 & 2500	845	800	990	400	400	400	900
Flip angle	4	8	9	8	11	11	11	9
Resolution (x/y/z in mm)	1/1/1	1.2/1/1	0.9/0.9/0.9	0.94/0.94/1	1/0.94/0.94	1.2/1/1	1/1/1.2	1.2/1/1
RsfMRI								
Eyes	Open	No instruction	Open/ no instruction	Open	Closed	Open	Open	Open
Sequence	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI
Phase encoding direction	A-P	P-A	A-P	A-P	P-A	P-A	P-A	P-A
Repetition time (ms)	2000	2000	2000	2000	2000	2500	2500	2500
Echo time (ms)	31	30	30	30	30	30	30	30
Flip angle	80	75	90	90	90	80	80	80
Resolution (mm, x/y/z)	3.5/3.5/3	3/3/3	3.75/3.75/5	4/4/4	3.44/3.44/3.5	3.31/3.31/3.2	3.31/3.31/3.2	3.31/3.31/3.2
Slice order	Interleaved	Ascending	Interleaved	Interleaved	Interleaved	Ascending	Ascending	Ascending
Slice gap (mm)	0	1	0	0	0	0.8	0.8	0.8
volumes	150	210	150	180	150	240	244	240

**Abbreviations**

FSPGR, fast spoiled gradient echo; GRE-EPI, gradient echo echo-planar imaging; IoPPN, Institute of Psychiatry, Psychology and Neuroscience, King's College London; JHU, Johns Hopkins University; KMU, Kanazawa Medical University; Kyoto, Kyoto University; MPRAGE, magnetization-prepared rapid gradient echo; MP2RAGE, magnetization-prepared 2 rapid acquisition gradient echoes; OSK2, Osaka University MRI2; OSK3, Osaka University MRI3; RsfMRI, resting-state functional magnetic resonance imaging; Tokyo, The University of Tokyo; TYM, University of Toyama

**Supplemental Figure 1. Reduced within-network connectivity in UHR, FEP, and ChrP patients.**




UHR (n=29) patients were compared to matched HC (n=25), FEP (n=81) with matched HC (n=109), and ChrP (n= 99) with matched HC (n=145). Yellow and \*\*\* indicate a significant reduction of connectivity in patients at  $p < 0.05$ , corrected for space (threshold-free cluster enhancement), two contrasts, and five NOIs. Orange and \*\* indicate trend-level significance at  $p < 0.1$ , corrected for space, contrast and NOI. Red and \* indicate significance at  $p < 0.05$ , corrected for space and contrast. Light blue indicates the NOIs.

#### Abbreviations

ACC, anterior cingulate cortex; BGN, basal ganglia network; ChrP, chronic schizophrenia; FEP, first-episode psychosis; HC, healthy controls; Ins, insula; MbThal, midbrain and thalamus; MTLN, medial temporal lobe network; NOI, network of interest; SN, salience network; Str, striatum; UHR, ultra-high risk.

**Supplemental Figure 2. Correlational analysis results.**



**a) Positive correlation between PANSS positive scale and connectivity in FEP (n=76).**

Yellow and \*\*\* indicate significance at  $p < 0.05$ , corrected for space by threshold-free cluster enhancement, two contrasts, and five NOIs. Orange indicates trend-level significance at  $p < 0.1$ , corrected for space, contrast and NOI. Red and \* indicate significance at  $p < 0.05$ , corrected for space and contrast. Light blue indicates the NOIs.

**b) Positive correlation between PANSS positive scale and static between-network connectivity in FEP (n=76).**

\*\*\* indicates significance at  $p < 0.05$ , corrected for two contrasts and 10 NOI-pairs. \* indicates significance at  $p < 0.05$ , corrected for contrast.

**Abbreviations**

ACC, anterior cingulate cortex; BGN, basal ganglia network; CAARMS, the Comprehensive Assessment of At-Risk Mental States; FEP, first-episode psychosis; Ins, insula; MbThal, midbrain and thalamus; MTLN, medial temporal lobe network; NOI, network of interest; PANSS, positive and negative syndrome scale; SN, salience network; Str, striatum; UHR, ultra-high risk.